Amneal Pharmaceuticals (AMRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.30
- Estimate
- $0.23
- Surprise
- +30.3%
- Score at report (before → after)
- 5.4 → 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Amneal Pharmaceuticals (AMRX) beat the $0.23 estimate with diluted EPS of $0.30 — a large 30.3% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AMRX Sell at 5.8/10.
3 of the last 4 quarters beat the estimate; this quarter's +30.3% surprise compares with a +34.7% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Customer: Cencora, McKesson, Cardinal Health, CVS Health (71.0%)
- Thin upside margin: 3.6%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.67
- Price target
- $18.27
- Stop
- $16.65
- Upside to target
- +3.4%
- Reward-to-risk
- 0.7:1
The stock trades at 37.2× trailing but 15.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
AMRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $6.22B
- P/E (fwd)
- 15.4
- P/E (ttm)
- 37.2
- 52-week range
- $9.44–$19.26
- Off 52-week high
- 8.3%
- RSI (14)
- 34
- Volume vs avg
- 0.08×
- Score today
- 5.8/10